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Abstract
Background and Aim: Calcium has been proposed as a mediator of the chemoprevention of colorectal cancer (CRC), but
the comprehensive mechanism underlying this preventive effect is not yet clear. Hence, we conducted this study to
evaluate the possible roles and mechanisms of calcium-mediated prevention of CRC induced by 1,2-dimethylhydrazine
(DMH) in mice.
Methods: For gene expression analysis, 6 non-tumor colorectal tissues of mice from the DMH + Calcium group and 3
samples each from the DMH and control groups were hybridized on a 4644 K Agilent whole genome oligo microarray, and
selected genes were validated by real-time polymerase chain reaction (PCR). Functional analysis of the microarray data was
performed using KEGG and Gene Ontology (GO) analyses. Hub genes were identified using Pathway Studio software.
Results: The tumor incidence rates in the DMH and DMH + Calcium groups were 90% and 40%, respectively. Microarray
gene expression analysis showed that S100a9, Defa20, Mmp10, Mmp7, Ptgs2, and Ang2 were among the most
downregulated genes, whereas Per3, Tef, Rnf152, and Prdx6 were significantly upregulated in the DMH + Calcium group
compared with the DMH group. Functional analysis showed that the Wnt, cell cycle, and arachidonic acid pathways were
significantly downregulated in the DMH + Calcium group, and that the GO terms related to cell differentiation, cell cycle,
proliferation, cell death, adhesion, and cell migration were significantly affected. Forkhead box M1 (FoxM1) and nuclear factor
kappa-B (NF-kB) were considered as potent hub genes.
Conclusion: In the DMH-induced CRC mouse model, comprehensive mechanisms were involved with complex gene
expression alterations encompassing many altered pathways and GO terms. However, how calcium regulates these events
remains to be studied.
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Introduction
The current incidence of colorectal cancer (CRC) is high, and
its prognosis remains poor [1]; hence, it is important to devise
strategies to prevent the development of CRC. Many agents are
used to prevent CRC [2]; however, there is no consistency in the
effects across agents [3,4,5], and some agents may lead to severe
side effects [6,7]. Thus, an alternative approach is necessary for
the prevention of CRC.
A recent systemic review revealed that calcium may be more
attractive in the prevention of CRC compared with aspirin
and screening [8]. However, the effectiveness of calcium is still
uncertain. Pooled findings of 10 cohort studies revealed a reverse
relationship between calcium intake and CRC risk [9], but this
relationship was not confirmed by a randomized controlled clinical
trial [10]. However, due to the limitations of the randomized
control trial (RCT), e.g., low dose of calcium, short length of
follow-up, and influence of estrogen intake [11], the conclusion
from the RCT was not convincing. Nonetheless, the effective-
ness of calcium on the prevention of CRC remains controversial
[12].
Similarly, the mechanism of calcium-mediated prevention of
CRC is not yet clear. In previous studies, calcium was thought to
reduce the risk of CRC by binding to toxic secondary bile acids and
forming insoluble soaps in the lumen of the colon [13], or by
reducing proliferation, stimulating differentiation, and inducing
apoptosis in the colonic mucosa [14,15]. A recent study suggested
that calcium could abrogate hyperplasia in the distal colon by
inhibiting a calcium channel receptor, i.e., transient receptor
potential channel, subfamily V, member 6 (TRPV6) [16]. These
findings indicate that calcium could reduce the risk of CRCthrough
a variety of mechanisms, but the specific and comprehensive
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,  jingyuanfang@yahoo.commechanism is yet not clear. Therefore, we conducted this study to
evaluate the possible roles and mechanisms of calcium-mediated
prevention of CRC induced by 1,2-dimethylhydrazine (DMH) in
mice. We believe that our findings will contribute to the research on
the clinical application of calcium.
Materials and Methods
Ethics Statement
Our study was approved by the Animal Care and Use
Committee of the Shanghai Jiao-Tong University School of
Medicine Renji Hospital, Shanghai, China. All animal procedures
were performed according to the guidelines developed by the
China Council on Animal Care and the protocol approved by the
Shanghai Jiao-Tong University School of Medicine, Renji
Hospital, Shanghai, China.
Chemicals
DMH was obtained from Sigma Chemical Co. (St. Louis,
MO,USA). Normal and high calcium feed for mice were obtained
from Shanghai SLAC Laboratory Animal Company (Shanghai,
China). The main components of the normal and high calcium feed
were the same: protein, 22.1%; fat, 5.28%; ash, 5.2%; fiber, 4.12%;
nitrogen-free extract, 52%; phosphorus, 0.92%; and Vitamin D3
6818.4 IU/kg. The concentration of calcium (in the form of
calcium carbonate) in the normal and high calcium feed was 1.24%
and 3.0%, respectively. The high calcium feed was adjusted by
adding calcium carbonate to obtain a final calcium content of 3%.
Because we think that the controversial effectiveness of highcalcium
diet on the prevention of CRC may be partially due to the small
dose of calcium in previous studies, so we decided to use higher
calcium content to test the exact preventive effect of CRC and the
mice’s tolerance.
Experimental animals
In total, 80 female Slac: ICR mice [weight, 18–20 g; grade,
specific pathogen-free (SPF)] were purchased from the Chinese
Academy of Sciences (Shanghai, China). They were maintained at
room temperature (22uC) with a relative humidity of 60% and 12-
hour light/dark cycles; they were supplied a standard laboratory
diet and drinking water. The mice were randomly divided into 4
groups (20 mice in each group): Control group, DMH group,
DMH+Calcium group, and Calcium group. The mice of the
Control group were provided normal feed and received subcuta-
neous injections of normal saline; those of the DMH group were
provided normal feed and received subcutaneous injection of
DMH at a dose of 20 mg/kg once weekly for 20 weeks; those of
the DMH+Calcium group were provided high-calcium feed and
received subcutaneous injection of DMH at a dose of 20 mg/kg
once weekly for 20 weeks; those of the Calcium group were
provided high-calcium feed and received subcutaneous injections
of normal saline. The mice were killed at the end of 24 weeks, and
the incidence of CRC in each group was examined. This method
has been described in detail in our previous study [17]. In brief,
longitudinal incisions were made in colorectal tissues to observe
the number of gross tumors. After then, the gross tumors were
removed separately and the full-thickness colorectal tissues were
cutted in half by the longitudinal axis. Some of the freshly obtained
tumor samples together with their half corresponding non-tumor
colorectal tissues were frozen immediately in liquid nitrogen. The
remaining samples were fixed in formalin solution and embedded
in paraffin blocks for pathological analysis and immunohisto-
chemistry.
Histological analysis
For histological analysis, 4-mm-thick sections of formalin-fixed,
paraffin-embedded colon tumors were prepared. After hematox-
ylin and eosin staining, the sections of each tumor were examined
under a light microscope (Olympus, Japan). The results were
confirmed by the pathologist Chen XY.
RNA extraction, labeling, hybridization, and analysis
Total RNAs from 12 non-tumor colorectal tissues [3 from the
Control group, 3 from the DMH group, 6 from the DMH +
Calcium group (among the 6 from the DMH + Calcium group, 3
were from mice with tumors and 3 were from mice without
tumors)] were harvested using TRIzol (Invitrogen) according to
manufacturer’s instruction. The RNA content was measured
using a Nanodrop ND-1000 spectrophotometer, and denaturing
gel electrophoresis was conducted. Next, the samples were
amplified, labeled using the Agilent Quick Amp labeling kit, and
hybridized using the Agilent whole genome oligo microarray
(Agilent Technologies, Palo Alto, CA) by using Agilent SureHyb
hybridization chambers. After hybridization and washing, the
processed slides were scanned with the Agilent DNA micro-
array scanner using the settings recommended by Agilent
Technologies.
The resulting text files extracted from the Agilent Feature
Extraction Software (version 10.5.1.1) were imported into the
Agilent GeneSpring GX software (version 11.0) for further analysis.
Background intensity has been cut off before normalization. The
microarray data sets were normalized in GeneSpring GX using the
Agilent FE one-color scenario (mainly median normalization).
Differentially expressed genes were identified by determining the
fold-change (FC) and p values of the t-test. Genes with an FC of
$1.5 and a p value of #0.05 between 2 groups were identified as
differentially expressed genes. Functional analysis of the differen-
tially expressed genes was performed using Gene Ontology (GO)
(http://www. geneontology.gov/) [18] and the KEGG PATH-
WAY Database (http://www. genome. jp/kegg/pathway.html).
Hub genes were identified using Pathway Studio (Ariadne
Genomics) [19].
Real-time polymerase chain reaction
Reverse transcription was performed using oligo (dT) primers
and superscript II reverse transcriptase (Takara). Quantification of
gene expression was performed using a real-time polymerase chain
reaction (PCR) kit (Takara). The expression level of 18 s rRNA
was used as an internal control. The expression of the following
genes was analyzed: S100a9, Defa20, Mmp10, Ptgs2, Per3, Tef,
Rnf152, and Prdx6. The primers are listed in Table 1.
Immunohistochemistry
Four-micrometer-thick sections of formalin-fixed, paraffin-
embedded non-tumor colon tissues were deparaffinized and
rehydrated. The microwave repair method was used for antigen
retrieval. Endogenous peroxidase activity was blocked by
incubation of the sections with 0.3% hydrogen peroxide for
10 min. Non-specific antigen was blocked by incubation of the
sections with sheep serum for 30 min. Slides were incubated
overnight at 4uC in a humidified chamber with rabbit mono-
clonal anti-b-catenin (Cell Signaling Technology, #9562) at a
dilution of 1:200. Anti-rabbit IgG was used as secondary antibody
(30 min incubation). Diaminobenzidine was used as chromogen
and the sections were counterstained with hematoxylin. Samples
incubated with PBS instead of primary antibody were used as
negative controls.
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The results of the animal experiments and real-time PCR were
analyzed using SAS 9.2 software (SAS Institute Inc. USA). Data
are presented as means 6 SD. Student’s t-test was used to




We successfully induced CRC in mice using DMH (Figure 1A).
Most of the cancers were identified as adenocarcinomas by
histological analysis (Figure 1B, 1C). In the DMH and DMH+Cal-
cium groups, the tumor incidence was 90% and 40% (Figure 1D),
the mean number of tumors per mouse was 5.3961.97 and
3.061.31 (Figure 1E), and mean maximum diameter of the tumors
was 6.4461.72 and 2.6361.19 (Figure 1F), respectively. No tumor
was found in the Control and Calcium groups. Growth and
development of the mice in the Calcium group were not signifi-
cantly affected, and the pathological examination of their kidneys,
hearts, lungs, livers, and spleens revealed no obvious abnormalities
(data not shown).
Gene expression profile by microarray analysis
All 12 colonic tissues cleared the quality control step and were
analyzed as described in the Methods section. The microarray
analysis was conducted between the Control group (3 samples),
DMH group (3 samples), and DMH + Calcium group (6 samples).
We also compared the gene expression levels between the samples
with or without tumors among the DMH + Calcium group.
Hierarchical clustering analysis of the 12 array expression data
showed a homogenous expression profile among the samples of
each group (Figure S1). By setting the filter for the FC to 61.5 and
the p value at #0.05, we found that the expression of 12395 genes
was significantly altered in the DMH group compared to those in
the Control group (see Table S1), and that of 1508 genes was
significantly altered in the DMH + Calcium group compared to
those in the DMH group (see Table S2). Compared with Table S1
and Table S2, we found that the expression of 549 genes whose
changes due to DMH treatment could be reversed by dietary
calcium (see Table S3). In Table 2, the 30 most differentially
expressed genes are shown, most of which are closely related to
tumorigenesis, such as S100a9 (S100 calcium-binding protein A9
[calgranulin B]), Defa20 (defensin alpha 20), Mmp10 (matrix
metalloproteinase 10), Ang2 (angiogenin, ribonuclease A family,
member 2), Per3 (period homolog 3), Tef (thyrotroph embryonic
factor), and Ptgs2 (prostaglandin-endoperoxide synthase 2). For the
8 selected genes, i.e., S100a9, Defa20, Mmp10, Ptgs2, Per3, Tef,
Rnf152, and Prdx6, the results obtained from the microarray
analysis were confirmed by real-time PCR (Figure 2). We selected
these genes for PCR confirmation because they are closely related
to tumorigenesis and worth further research.
To determine whether specific biological pathways or functional
gene groups were differentially affected by the high calcium diet, we
analyzed our microarray dataset (on the basis of the results shown in
Table S3) using the GO and KEGG software. The detailed results
are shown in Table S4 and Table S5. By setting the p value at
#0.05, we found significant downregulation of 39 signaling path-
ways, including some tumor-related pathways such as the cell cycle
pathway,Wntsignaling pathway,vascularendothelialgrowthfactor
(VEGF) signaling pathway, and transforming growth factor (TGF-
b) signaling pathway. The most enriched pathways are shown in
Table 3. We used immunohistochemistry to detect the protein
expression and distribution of b-catenin, the core molecule in the
Wnt pathway, and found that its expression was significantly higher
in the non-tumor colonic mucosa from the DMH group than in that
from the Control group, however, its expression in the DMH +
Calcium group was markedly reduced compared with the DMH
group (Figure 3). Altogether, 703 GO terms, including tumor-
related GO terms such as cell differentiation, cell proliferation,
apoptosis, angiogenesis, cell adhesion, cell cycle, and cell division,
were significantly changed.
We also used Pathway Studio software to filter hub genes that
may play key roles in the calcium-mediated prevention of CRC
(Table 4). Of those, 2 genes were selected to construct gene
networks (Figure 4). On the basis of the networks, we could clearly
determine the core roles of the hub genes.
In addition, we further compared the gene expression levels
among the mice from the DMH + Calcium group with/without
tumors and found that the gene expression levels of most of the
above selected genes in mice from the DMH + Calcium group
with tumors was between those from the DMH + Calcium group
without tumors and those from the DMH group (see Table S6 and
Figure S1). We also found that the expression of some calcium
transporters was different among the mice from the DMH +
Calcium group with/without tumors. For example, the expression
of Trpv6 and Trpv3 was significantly upregulated in mice from the
DMH + Calcium group with tumors compared to those without
tumors; however, the expression of plasmalemmal Ca
2+-ATPase
(PMCA) was significantly downregulated.
Table 1. Primer sequence.
Gene name Forward sequence Reverse sequence Product length
S100a9 59-AACATCTGTGACTCTTTAGCCTTG-39 59-ACTGTGCTTCCACCATTTGTCT-39 169
Mmp10 59-CCCAGCTAACTTCCACCTTTC-39 59-AGCAGGATCACATTTGTCTGG-39 142
Defa20 59-AGGCTGTGTCTGTCTCCTTTG-39 59-TGAGCAGGTCCCATAAACTTG-39 128
Ptgs2 59-GAGTGGGGTCATGAGCAACTA-39 59-CTGGAACTGCTGGTTGAAAAG-39 153
Per3 59-CACCTCTTCGAGTGAGTCCAG-39 59-CCAGTATCCGTGGTGCTTTTA-39 246
Tef 59-TCTTCCTCTACTGCCATCTTTCA-39 59-AAGTTCACATCGACCTCCACAC-39 122
Rnf152 59-AGTCATTGCCATACCACACACTT-39 59-GAGTGTACGCTCCTTAGAGATGG-39 106
Prdx6 59-AAGTTAGACACACAGCCACAA-39 59-ACTTGGCACCGTAGTTTTGTTT-39 120
18S rRNA 59-CGGACAGGATTGACAGATTGATAGC-39 59-TGCCAGAGTCTCGTTCGTTATCG-39 150
doi:10.1371/journal.pone.0022566.t001
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In this study, we used the DMH-induced CRC mouse model
that shows phenotypic and genotypic features similar to those
observed in human sporadic CRCs and, thus, can be applied to
study the prevention of CRC [20]. In this study, we found that the
incidence of CRC decreased significantly in mice fed a high
calcium diet, indicating a clear role of calcium in the prevention of
CRC. Our results are consistent with many other studies. Pence
[21] have found that rats on the high calcium diet have a
decreased CRC incidence compared to the low calcium diet (86%
vs. 53%), Salas [22] also observed a significant diminution in the
number of tumors and a decrease in the CRC incidence in the
group fed high calcium diet (97% vs. 64%). However, some studies
have observed different outcomes. Sitrin [23] found that neither
calcium supplementation alone nor supplemental calcium con-
junction with vitamin D deficiency altered the incidence of CRC
induced by DMH, Mølck [24] even found an increased incidence
in the rats fed high calcium diet. We think that the differences in
the animal strain, animal age, rearing environment, basis diet,
DMH doses and duration of injection, calcium concentration,
calcium intervention time may be accounted for the differences in
the outcome of various studies using high calcium. The confirmed
preventive effectiveness of CRC with high calcium diet could not
yet be contained from those studies. We think it is may be due to
the small doses of calcium in those studies. So we used higher
calcium content(3%) in the feed to test the preventive effect of
CRC and the mice’ tolerance. In fact, this high calcium feed
showed good preventive effect of CRC in our experiment and no
obvious adverse effects was found in mice. In addition, no tumor
was found in the Calcium groups. Growth and development of the
mice in the Calcium group were not significantly affected, and the
pathological examination of their kidneys, hearts, lungs, livers, and
spleens revealed no obvious abnormalities, the expression of most
of the selected genes confirmed by real-time PCR in the Calcium
group was equal to that in the Control group. These findings
indicate that this high calcium diet is safe for the mice.
Next, we used microarray gene expression profile analysis to
determine the mechanism of calcium-mediated prevention of
CRC. To the best of our knowledge, this is the first investigation to
use microarray technology for studying the role of high calcium
diet in the prevention of CRC.
When the FC was set to $1.5, the changes in 549 genes that
were the result of DMH treatment could be reversed with dietary
calcium. S100a9 is the most downregulated gene; its product is a
cytoplasmic Ca
2+-binding protein. Although extracellular S100a9
could induce apoptosis by binding to a yet unknown receptor and
cause dimerization of Bax and Bak and their translocation to the
mitochondria leading to mitochondrial damage [25], its expression
in epithelial cells could indeed induce cell proliferation by
activating the phosphoinositide 3-kinase (PI3K)–Akt–NF-kB
survival pathway, which is associated with tumorigenesis [26]. In
Figure 1. Main results of the animal experiment. A. Observation of tumors in the large bowel of mice after sacrifice at 24 weeks. B (6200) and C
(6400). Most of the tumors were confirmed as adenocarcinomas by pathological examination. D. Tumor incidence among the 4 groups. E. Tumor
number/mice among the 4 groups. F. Maximum tumor diameter among the 4 groups (Control: Control group, received normal feed and injection of
normal sodium for 20 weeks; DMH: DMH group, received normal feed and injection of DMH for 20 weeks; DMH+Calcium group: received high-
calcium feed and injection of DMH for 20 weeks; Calcium group: received high-calcium feed and injection of normal sodium for 20 weeks). * P
value,0.05 between DMH+Calcium group and DMH group.
doi:10.1371/journal.pone.0022566.g001
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involved in innate immunity, and its expression was found to be
elevated in numerous pathological conditions associated with
inflammation [27]. Many other inflammatory cytokines, such as
Defa, were also significantly downregulated [members of the
defensin family were downregulated at different levels: Defa-rs2
(FC=29.88), Defa20 (FC=28.16)]. Tumor necrosis factor (Tnf)
and its receptors were also downregulated at different levels: Tnf
(FC=21.87), Tnfrsf11b (FC=25.98), Tnfrsf19 (FC=22.27).
Several other studies performed using the DMH or azoxymethane
(AOM)-induced CRC model also found high expression levels of
S100a9 and Defa in tumor tissues [28,29]. Inflammatory cytokines
play important roles in the innate and adaptive immunity;
however, those elevated cytokines are also involved in tumor
initiation, promotion, and invasion [30,31,32,33], and thus, play
an important role in inflammation-associated carcinogenesis [34].
MMPs are a family of matrix metalloproteinases that can play
important roles in the tumor microenvironment [35]. Many
members of the MMP family were significantly downregulated
in the DMH + Calcium group [MMP10 (FC=29.47), MMP13
(FC=29.1), MMP7 (FC=27.07), and MMP11 (FC=21.56)].
Other metalloproteinases were also downregulated, such as Adam8
and Adam10, which were downregulated by 2.08 and 1.6 times,
respectively. Recent studies have shown that many members of the
MMP and ADAM family could play various roles in tumorigen-
esis. For example, MMP7 could cleave Fas ligand, thereby
lowering the impact of chemotherapy on the tumor by abrogating
apoptosis [36]. Adam10 may trigger the release of soluble
epidermal growth factor (EGF), mediate the shedding of E-
cadherin, translocating b-catenin to the nucleus, and thus, driving
cell proliferation [37]. However, the most important role of the
members of the MMP and ADAM family is promoting tumor
invasion and metastases by degrading extracellular matrix [38,39].
These findings indicate that a high calcium diet may play an
important role in inhibiting invasion and metastases of CRC.
Because in vitro studies showed that, in CRC cells, E-cadherin
Table 2. List of the most differentially expressed genes whose changes due to DMH treatment could be reversed by diatery
calcium.
Accession number Gene symbol Gene Description Fold change P value
NM_007847 Defa-rs2 defensin, alpha, related sequence 2 29.88 1.93E-04
NM_009114 S100a9 S100 calcium binding protein A9 29.58 4.25E-05
NM_019471 Mmp10 matrix metallopeptidase 10 29.47 7.67E-07
NM_008607 Mmp13 matrix metallopeptidase 13 29.10 1.48E-04
NM_183268 Defa20 defensin, alpha, 20 28.16 1.20E-04
NM_010810 Mmp7 matrix metallopeptidase 7 27.07 0.00411071
EU817850 Gm5222 monoclonal antibody 1D6 immunoglobulin light chain variable region 26.98 1.99E-05
NM_008764 Tnfrsf11b tumor necrosis factor receptor superfamily, member 11b 25.98 0.01292794
NM_011915 Wif1 Wnt inhibitory factor 1 25.79 0.00447852
NM_001174099 Krt36 keratin 36 25.79 2.75E-04
NM_009263 Spp1 secreted phosphoprotein 1 25.40 1.31E-04
NM_175391 Apol7c apolipoprotein L 7c 24.93 5.03E-07
NM_007969 Expi extracellular proteinase inhibitor 24.78 3.00E-02
NM_008256 Hmgcs2 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 24.62 9.86E-06
NM_010743 Il1rl1 interleukin 1 receptor-like 1 24.38 1.28E-05
NM_026414 Asprv1 aspartic peptidase, retroviral-like 1 24.38 2.82E-05
NM_007449 Ang2 angiogenin, ribonuclease A family, member 2 24.34 0.04452419
NM_053080 Aldh1a3 aldehyde dehydrogenase family 1, subfamily A3 24.11 0.01939012
NM_007440 Alox12 arachidonate 12-lipoxygenase 24.03 0.02319294
NM_001142959 Bcl2l15 BCLl2-like 15,transcript variant 1 23.95 5.27E-04
NM_016958 Krt14 keratin 14 23.81 0.00713059
NM_007753 Cpa3 carboxypeptidase A3 23.74 3.03E-05
NM_008939 Prss12 protease, serine, 12 neurotrypsin 23.65 0.04354441
NM_011280 Trim10 tripartite motif-containing 10 23.58 3.46E-06
NM_001082531 Pla2g2a phospholipase A2, group IIA 23.50 8.61E-04
NM_021285 Myl1 myosin, light polypeptide 1 23.31 9.72E-04
NM_011067 Per3 period homolog 3 3.16 2.08E-05
NM_153484 Tef thyrotroph embryonic factor 2.98 1.26E-05
NM_011198 Ptgs2 prostaglandin-endoperoxide synthase 2 22.87 1.53E-04
AK081980 Prdx6 16 days embryo head cDNA, product:peroxiredoxin 5 2.87 0.01674954
NM_178779 Rnf152 ring finger protein 152 2.63 0.0028878
Fold changs and P values are the results comparing DMH+Calcium group and DMH group.
doi:10.1371/journal.pone.0022566.t002
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Relative mRNA expression was calculated according to the 2
2DDT method. Data are the mean of 10 samples 6 SD. Control, gene expression level in
the normal colon tissue of mice in the Control group; DMH, gene expression level in the non-tumor colon tissue of mice in the DMH group;
DMH+Calcium, gene expression level in the non-tumor colon tissue of mice in the DMH+Calcium group; Calcium, gene expression in the non-tumor
colon tissue of mice in the Calcium group. * P value,0.05 between DMH+Calcium group and DMH group; 1 P value,0.05 between Calcium group
and Control group.
doi:10.1371/journal.pone.0022566.g002
Table 3. The most enrichment pathways by KEGG.
Pathway ID Pathway name Selection Count Count Enrichment
Down-regulated pathways
mmu04310 Wnt signaling pathway 11 148 5.123285
mmu05140 Leishmaniasis 6 67 3.468583
mmu04110 Cell cycle 8 127 3.383628
mmu04370 VEGF signaling pathway 5 76 2.378304
mmu04010 MAPK signaling pathway 10 272 2.299372
mmu04114 Oocyte meiosis 6 114 2.277315
mmu04664 Fc epsilon RI signaling pathway 5 81 2.260629
mmu04350 TGF-beta signaling pathway 5 84 2.194259
mmu05222 Small cell lung cancer 5 84 2.194259
mmu04640 Hematopoietic cell lineage 5 85 2.172789
mmu00590 Arachidonic acid metabolism 5 86 2.151633
mmu04012 ErbB signaling pathway 5 88 2.110233
mmu00650 Butanoate metabolism 3 30 2.084872
mmu05216 Thyroid cancer 3 30 2.084872
Up-regulated pathways
mmu00982 Drug metabolism - cytochrome P450 8 85 7.972006
mmu04710 Circadian rhythm - mammal 4 22 5.391566
mmu00591 Linoleic acid metabolism 3 45 2.827674
mmu00910 Nitrogen metabolism 2 23 2.231527
mmu00980 Metabolism of xenobiotics by cytochrome P450 3 75 2.197296
mmu00830 Retinol metabolism 3 78 2.150205
mmu03320 PPAR signaling pathway 3 81 2.105092
‘‘SelectionCounts’’ stands for the Count of the DE genes’ entities directly associated with the listed PathwayID;
‘‘Count’’ stands for the count of the chosen background population genes’ entities associated with the listed PathwayID;
‘‘Enrichment_Score’’ stands for the Enrichment Score value of the PathwayID, it equals ‘‘2log10(Pvalue)’’.
doi:10.1371/journal.pone.0022566.t003
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2+
concentration [40], calcium may be considered to suppress the
epithelial-mesenchymal transition (EMT) to inhibit CRC metas-
tases.
Per3 was the most upregulated gene in our study, belonging
to the period genes. Those genes are core elements of the
transcriptional/translational feedback loops that generate the
endogenous circadian rhythm, and Per3 participates in timekeep-
ing in the pituitary and lung [41]. Recent studies have suggested
that circadian genes participate in the growth and development of
various cancers, and the period genes have now been linked to
DNA damage response pathways, inhibition of the growth of
cancer cells, and increase in the apoptotic rate [42]. Oshima’s
study has shown that the expression of Per3 in CRC tissues was
significantly lower than that in the adjacent normal mucosa,
suggesting that Per3 may function as a tumor suppressor gene [43].
Tef was the second most upregulated gene in our study. It
belongs to the PAR-domain basic leucine zipper (PAR bZip)
transcription factors and is involved in detoxification and drug
metabolism [44] and in the maintenance of cell shape in fibro-
blasts [45]. It also serves as a pro-apoptotic gene by promoting the
expression of bcl-gs or bik [46,47]. Many other genes were also
upregulated, e.g., Rnf152 and Prdx6. Rnf152 is a novel RING
finger protein and has been shown to have pro-apoptotic activity
[48]. Prdx6 is a member of the PRDX family, associated with
functions such as cell proliferation, differentiation, and apoptosis,
thus executing anti-cancer activity [49].
By using pathway analysis, we found that the Wnt pathway was
significantly affected. Although the expression of the Wnt
inhibitory factor wif1 was significantly downregulated, that of
many genes associated with the Wnt signaling pathway and their
target genes was downregulated [i.e., Tcf7, Myc, cyclin d1 (Ccnd1),
and Mmp7 at FC of 21.53, 21.61, 21.62, and 27.07,
respectively]. The protein expression of b-catenin was significantly
reduced in the DMH + Calcium group, suggesting that the Wnt
pathway was downregulated in this group. This is consistent with
previous findings [28,50]. Interestingly, the cell cycle pathway was
also significantly inhibited in the DMH + Calcium group, with
many genes in this pathway being consistently downregulated, i.e.,
the cyclins Ccnb1 and Ccnd1 were downregulated by 1.79 and 1.62
times, respectively, and the expression of the cyclin-dependent
kinase Cdk1 was reduced by 1.66 times.
Among the metabolic pathways, the arachidonic acid pathways
were significantly inhibited in the DMH + Calcium group. Many
Figure 3. Expression of b-catenin in the non-tumor colorectal mucosa in the 4 groups determined by immunohistochemistry.
Control, Control group; DMH, DMH group; DMH+Calcium, DMH+Calcium group; Calcium, Calcium group.
doi:10.1371/journal.pone.0022566.g003
Table 4. Partial list of the hub genes.
Name Total No.of targeted genes No.of overlap genes Percent overlap Gene set seed P value
Expression Targets of Jun/Fos 542 68 12% Jun/Fos 1.55E-08
Expression Targets of PKA 369 52 14% PKA 2.03E-08
Expression Targets of EGF 504 64 12% EGF 2.71E-08
Expression Targets of FOXM1 108 24 22% FOXM1 4.04E-08
Expression Targets of TP53 538 65 12% TP53 1.41E-07
Expression Targets of MYOCD 36 13 35% MYOCD 1.66E-07
Expression Targets of NF-kB 742 76 10% NF-kB 8.28E-06
Expression Targets of TNF 900 87 9% TNF 1.69E-05
doi:10.1371/journal.pone.0022566.t004
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also known as cyclooxygenase-2 (COX-2), was reduced by 3 times.
The arachidonic acid pathway is activated during inflammation,
leading to the synthesis of prostaglandin and thromboxane, which
play an important role in inflammatory response [51]. Further-
more, the key enzyme in this pathway, Ptgs2 (COX-2), plays an
important role in the initiation of CRC. COX-2 overexpression
was shown to be correlated with carcinogenesis in more than 80%
of CRCs [52]. In animal models, COX-2 expression was found to
be sufficient to induce tumorigenesis [53]. The mechanism may be
related to the activation of inducible nitric oxide synthase (iNOS)
and VEGF signaling to promote formation of new blood vessels
[54]. On the basis of the finding that the expression of the
inflammatory cytokines S100a9, Defa, TNF, and TNF receptors
was also significantly downregulated in the DMH+Calcium group,
we speculated that calcium may play an important role in reducing
inflammation-related tumorigenesis.
Among the Pathway Studio-derived hub genes, which may play
key roles in the calcium-mediated prevention of CRC, FoxM1, NF-
kB, etc., were also involved. FoxM1 belongs to a family of evolu-
tionarily conserved transcriptional regulators that were character-
ized by the presence of a DNA-binding domain known as the
forkhead box domain. Higher expression of FoxM1 was noted in
many types of human cancers [55]. FoxM1 may play important
roles in cell proliferation and apoptosis [56]. The molecular
mechanism underlying FoxM1 signaling-mediated induction of
tumor growth has not been completely elucidated. However,
multiple oncogenic pathways such as PI3K/Akt, NF-kB, extra-
cellular signal-regulated kinase (ERK), mitogen-activated protein
kinase (MAPK), VEGF, reactive oxygen species (ROS), c-myc,
and hypoxia-inducible factor (HIF)-1 have been reported to
interact with FoxM1 signaling; this suggests that the interaction
between FoxM1 signaling and other signaling pathways may play
important roles in tumorigenesis [57]. It should be noted that the
expression of many genes regulated by NF-kB showed altered
expression in the DMH + Calcium group, e.g., TNF, PTGS2,
MYC, CCND1, ETS-related gene 1 (ERG1), S100A9, and lymphoid
enhancer factor 1 (LEF1), suggesting that NF-kB may also serve as a
hub gene in the calcium-mediated prevention of CRC. Although
the expression of NF-kB did not change significantly at the
transcriptional level, it may have changed at the translational or
posttranslational level. The expression pattern of NF-kB in the
DMH + Calcium group and its specific mechanism needs to be
further elucidated.
We alsofound that thegene expression levelsofmost ofthe above
selected genes in mice from the DMH+Calcium group with tumors
was between those from the same group without tumors and those
from the DMH group, thus confirmed the importance of those
genes in the calcium’s prevention of CRC. Interestingly, the
expression of some calcium transporters, such as Trpv6, Trpv3 and
PMCA, was different among the mice from the DMH + Calcium
with/without tumors. One of the biological functions of these
calcium transporters is to mediate transcellular Ca
2+ movement
across epithelial cells [58]. Therefore, the differential expression of
these calcium transporters disrupted the distribution of intracellular
and extracellular calcium, thereby activating the proliferation-
related pathways [59]. Hence, we speculated that the dif-
ferential expression of these calcium transporters may partially
account for the different expression levels of the selected genes.
It is necessary to mention the limitations of this study. First, we
used colorectal tissues instead of colorectal mucosa in our micro-
array study. There are many different types of cells in the colorectal
tissues, so it is hard to determine the cellular origin of the identified
genes in this study. However, more and more evidences have shown
that the stroma and immune cells play important roles in the tumor
initiation. In our studies, we have found that there are many
immune cells infiltrated into the colorectal tissues by pathological
examination and the expression of many inflammation cytokines
is significantly upregulated in the DMH group compared with
Control group. These cells can not only cause local inflammation,
but also significantly promote tumorigenesis [34]. We also have
found that high calcium diet could reduce the expression of many
inflammation cytokines, suggesting that calcium may play an
important roles in the prevention of inflammation-related tumor-
igenesis. Therefore we believe that using colon tissues instead of
colon mucosa could reflect the overall and more realistic changes in
Figure 4. Potential hub genes derived from Pathway studio software. The differentially expressed genes regulated by the 2 hub genes
(A,FoxM1;B, NF-kB) are displayed in form of a network diagram. Green or red coloring, sequences that are downregulated or upregulated in the
DMH+Calcium group compared with the DMH group, respectively. The intensity of the color is proportional to the extent of change.
doi:10.1371/journal.pone.0022566.g004
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used in the study of gene expression associated with CRC [60,61].
Second, since we did not use semi-purified diets in our animal
experiment, our results may be biased. Third, the calcium content
in our study was rather high. Although this may account for the
drastic effectiveness in the prevention of CRC and no obvious
adverse effect was found in the mice in our study, it is difficult to
apply it for the prevention of sporadic CRC in humans, because
exceedingly high calcium and vitamin D concentrations in the diet
may pose a risk for developing hypercalcemia and kidney stones.
However, a meta-analysis found that a calcium intake of more than
1000 mg/day will have a better preventive effect [62]. Another
clinical trial found that a lower calcium intake may have no
apparent preventive effect [10]. Therefore, further study is
necessary to confirm the optimal calcium content in the prevention
of CRC.
In conclusion, we confirmed the effectiveness of calcium to
prevent CRC in the DMH-induced CRC mouse model. We also
clarified the comprehensive mechanisms of calcium-mediated
prevention of CRC. Our results showed that calcium exerted its
protective effect mainly by downregulating the expression of
oncogenes such as S100a9, Mmp10, Adam8, and Ptgs2, by inhibiting
the activity of tumor-associated pathways such as the Wnt and cell
cycle pathway, and by negatively regulating cell proliferation, cell
division, cell invasion, and angiogenesis. In particular, calcium is
speculated to play important roles in reducing inflammation-
associated tumors and suppressing tumor invasion and metastases.
However, the mechanism of the calcium-mediated regulation of
these genes remains to be studied.
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